Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $228 | In Stock | |
5 mg | $589 | In Stock | |
10 mg | $993 | In Stock | |
25 mg | $1,470 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer. |
Targets&IC50 | MIAPaCa2 cells:2.95 μg/mL |
In vitro | Tigatuzumab showed sensitivity to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 μg/mL and 8.21 μg/mL, respectively.[1] Tigatuzumab (3-8 μg/mL; 5 hours) was able to induce apoptosis in cancer cells. [1] |
In vivo | Tigatuzumab (3 mg/kg; i.v.; once weekly for 4 weeks) was effective in inhibiting tumor growth of human pancreatic cancer MIA PaCa-2-RFP in a xenograft mouse model. [1] |
Alias | TRA-8, TRA8, CS-1008, CS1008, Anti-Human TRAIL-R2 Recombinant Antibody |
Molecular Weight | 144.6 (kDa) |
Cas No. | 918127-53-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.